Local policy "red envelopes" to promote high-quality development of the industry The cumulative number of domestic drugs and Class II and III medical devices approved in Guangzhou in the past three years hit a new high
The biopharmaceutical industry is one of the most innovative emerging industries in the world, and Guangzhou is taking the lead in building a world-class biopharmaceutical industry cluster.
Guangzhou's biopharmaceutical industry has been included in the first batch of national strategic emerging industry clusters and the list of implementation entities of the national "Hundred Cities and Hundred Parks" action.
Local policies continue to "red envelopes", and the industry has continued to develop with high quality along the way.
Just recently, the "Guangzhou Huangpu District Guangzhou Development Zone Implementation Opinions on Accelerating the Development of the Biopharmaceutical Industry (Revised)" was issued and implemented, valid until January 9, 2023. Units engaged in R&D, production and service in the fields of chemical medicine, medical equipment, biomedical engineering and other biomedical industries shall provide support.
Li Yuqiang, the main unit of Guangzhou biopharmaceutical and high-end medical device chain and secretary-general of Guangzhou Bioindustry Alliance, told the Guangzhou Daily all-media reporter: "Guangzhou's biopharmaceutical industry has maintained an average annual growth rate of about 10%, and the number of enterprises has ranked first in the country. Third, by 2023, the city's biopharmaceutical and high-end medical device industry scale will strive to exceed 600 billion yuan."
Text/Picture/Table Guangzhou Daily All Media Reporter Tu Duanyu Zhao Fangyuan
Policies bring agglomeration effect, the number of listed companies in Guangzhou biopharmaceuticals is close to 50
GPHL has successfully entered the ranks of the world's top 500 companies, Lane Pharmaceuticals and other companies have been selected as national-level "specialized, special and new" small giant companies, and BeiGene has become the world's first biological company listed in the US stock market, Hong Kong stock market and A-share market. Pharmaceutical companies... Li Yuqiang counted the local achievements one by one and said that Guangzhou has been actively cultivating the biopharmaceutical industry, laying a good job in the advanced industrial foundation and the modernization of the industrial chain. At present, it has initially formed scale, clustering, integration and ecologicalization. The development advantage and leading position, the overall level ranks among the first echelon of the country.
"Since 2019, Guangzhou has continuously implemented "Guangzhou City's Implementation Opinions on Accelerating the Development of Biomedical Industry", "Guangzhou City's Several Regulations on Accelerating the Development of Biomedical Industry", "Guangzhou City's Biomedical Industry Chain Development Promotion Plan", "Guangzhou City Biomedical Industry Development Promotion Plan" Policy measures such as the Action Plan for the High-Quality Development of the High-end Medical Device Industry (2021-2023)" have promoted the high-quality development of the biomedical industry, making Guangzhou's biomedical agglomeration effect initially apparent. According to incomplete statistics, from 2019 to 2021 , the number of biopharmaceutical companies in Guangzhou has increased from more than 3,800 to more than 6,400, ranking third in the country. Since 2020, 8 new listed companies have been added, the number of listed companies is close to 50, and the market value ranks fourth in the country.” Li Yuqiang said , behind the numbers, it is Guangzhou that focuses on building a complete industrial chain covering upstream technology research and development, clinical trials, midstream transformation and pilot testing, production and manufacturing, downstream market applications, and circulation and sales, focusing on cultivating a large number of high-tech, market prospects. A biopharmaceutical company with great development potential.
In addition, according to the statistics of Guangzhou Bio-Industry Alliance Research Institute, Guangzhou has established all 6 drug non-clinical safety evaluation institutions (GLP) in Guangdong Province and nearly half of the province, a total of 39 drug clinical trial institutions (GCP) and biomedical fields. A large number of new drug research and development platforms such as key laboratories and engineering centers.
Since 2021, "aircraft carrier-level" strategic scientific research forces such as the Guangzhou laboratory and human cell lineage have been implemented; the two national engineering research centers of Baiyunshan Kampo and Jida Gene have been included in the national new sequence management; Xiangxue Pharmaceutical and Wanfu Bio have been approved by the state Level enterprise technology center; new drug application service center and innovative drug clinical trial service center, etc.
Looking at the overall framework of Guangzhou's national bio-industry development, it has now formed a coordinated development of characteristic parks such as R&D in Bio Island, pilot test in Science City, manufacturing in Knowledge City, Guangzhou Health Medical Center, Baiyun Biomedical Industry Base, and International Medical Port. The new development pattern of "three centers radiating multiple regions".
Layout around "one axis, four cores and multiple points"
Guangzhou Science and Technology Innovation "14th Five-Year Plan" Announces New Opportunities for Biomedical Industry
On February 17, the "14th Five-Year Plan for Science and Technology Innovation in Guangzhou" announced on the website of the Guangzhou Municipal People's Government proposed to build a functional layout of science and technology innovation space based on "one axis, four cores and multiple points". Come to a number of new development opportunities.
According to the layout, in the scientific and technological innovation axis (Huangpu section), Guangzhou International Bio Island relies on the national laboratories, provincial laboratories and other advantageous resources to focus on the development of cutting-edge technologies and innovative products in the fields of life sciences, biotechnology and innovative drugs, to create an international It is a biotechnology and pharmaceutical research and development and industrialization base, and a national-level bio-industry research and development and pilot test base.
At the same time, it will cultivate three world-class industrial clusters of a new generation of information technology, artificial intelligence and biomedicine.
In the Sino-Singapore Guangzhou Knowledge City, which is one of the "four cores", vigorously develop the world's top biopharmaceutical industries and build a value innovation park such as biopharmaceuticals.
In the life and health industry innovation zone of the Guangdong-Hong Kong-Macao Greater Bay Area, "one district and two centers" will be built to create a life and health industry innovation zone with one core, one axis and five parks as the pattern.
Guangzhou International Bio-Island will build a national biomedical policy innovation pilot zone and build the world's top biomedical and biosafety R&D center.
Gather biopharmaceutical enterprises, and gradually form the advantage of high-end industry aggregation.
Accelerate the research and development of new traditional Chinese medicines
The reporter noted that the development of modern Chinese medicine is also regarded as a major focus.
The plan proposes that priority should be given to the research on the modern technology of traditional Chinese medicine and ethnic medicine based on fixed-dose combination, the development of new traditional Chinese medicine drugs that focus on major diseases for the clinical treatment of dominant diseases in traditional Chinese medicine, and accelerate the promotion of classic compound prescriptions in the field of traditional Chinese medicine, traditional Chinese medicine classics, and in-hospital preparations in medical institutions. Research and development of new traditional Chinese medicines for the main source.
Accelerate breakthroughs in the research and development technology of traditional Chinese medicine and ethnic medicine, advanced pharmaceutical and efficacy evaluation technology based on big data.
Actively promote the research and development of a number of advanced Chinese medicine equipment and important pharmaceutical equipment.
In fact, GPHL is the first company in the world to enter the world's top 500 companies with traditional Chinese medicine as its main business. Li Chuyuan, secretary of the party committee and chairman of GPHL, said that by creating "fashionable traditional Chinese medicine", we will strive to make the "tide" Chinese medicine Medicine will soon become the mainstream health solution in the world.
In terms of research and development of new traditional Chinese medicines, the first landing project after the establishment of the Macau International Headquarters of GPHL is the industrialization of scientific research achievements of Baiyunshan Isatidis and Compound Isatis. Carry out the development of improved new drugs, and the development of the same name and the same formula for Baiyunshan Compound Banlangen Granules according to the qualitative changes in the process, so as to realize the overall technology, quality, efficacy improvement and product upgrading of Baiyunshan Banlangen Granules and Compound Banlangen Granules.
Promote the development of the industry to the high end of the value chain and innovation chain
In recent years, Guangzhou has coordinated and promoted the reform of the "three medical linkages" of medicine, medical care and medical insurance, improved the ecological construction of the entire biomedicine and health industry chain, and promoted the transformation of major innovative scientific and technological achievements to realize the transformation of samples-products-commodities.
According to the data of Guangzhou Bio-Industry Alliance, from 2019 to 2021, Guangzhou has approved a total of 3,247 domestic drugs, 149 new drug clinical approvals, 1,127 Class II and III medical devices, and devices that have entered the innovation review and priority approval procedures have been approved 33 indivual.
Facing the opportunities and challenges brought by the spread of the global new crown pneumonia epidemic, the cumulative number of approvals for Guangzhou-made drugs and Class II and III medical devices in the past three years has reached a record high.
This plan proposes to accelerate the integration of biotechnology and information technology, and help promote the development of the state's biomedical industry to the high-end of the value chain and innovation chain.
In terms of inspection and detection and precision medical technology, priority is given to the research of cell and protein biopharmaceutical activity detection technology, breakthroughs in precise diagnosis and efficacy evaluation technology based on molecular detection and molecular imaging, key technologies for the research and development of small desktop high-throughput gene sequencers, virus Nucleic acid molecule detection and related technologies.